Login to Your Account

The Persistence of Memory

Engineered T Cells May Boost Melanoma Treatment Yervoy

By Anette Breindl

Thursday, April 28, 2011
Like many cancer treatments, recently approved melanoma drug ipilimumab (Yervoy, Bristol Myers Squibb Co.), is great for those patients in whom it works – meaning, not that many. In Yervoy's case, the response rate is about 15 percent. (See BioWorld Today, March 28, 2011, and March 23, 2011.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription